An AI-powered molecular engineering platform has just closed a Series B funding round, securing $130 million in capital with General Catalyst leading the investment. The company's approach leverages artificial intelligence to design and optimize molecular structures more efficiently than traditional methods. This funding milestone reflects growing investor confidence in AI-driven drug discovery and materials science innovation. The capital injection positions the team to accelerate development, scale operations, and expand their technology's real-world applications across pharma and advanced materials sectors. Worth keeping on radar as a case study in how computational biology and machine learning are reshaping molecular design workflows.